Clinical Trial Update: GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating methotrexate for GVHD prophylaxis in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide (Phase 1/…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematopoietic Neoplasms

Drugs mentioned

• METHOTREXATE (METHOTREXATE)
• Posttransplant Cyclophosphamide (Cyclophosphamide)

Snippet

Sponsor: University of Sao Paulo General Hospital | Conditions: Graft Vs Host Disease, Hematopoietic Neoplasm | Phase 1, Phase 2 | Status: UNKNOWN